## Lymphocyte mRNA as a resource for detection of mutations and polymorphisms in the CF gene

Gillian Chalkley, Ann Harris

The most common mutation in the cystic fibrosis gene, deletion of a phenylanaline residue at amino acid 508, occurs in about 70% of CF patients in North America and northern Europe.<sup>12</sup> A collection of alternative mutations in the CF gene has already been defined by members of the CF Genetic Analysis Consortium. Most of these mutations have been detected by amplification of individual CF gene exons from genomic DNA followed by DNA sequence analysis. Clearly this approach is laborious since each of the 27 exons has to be analysed independently. An alternative means of searching for mutations is through the examination of mRNA. This would enable much larger segments of the gene to be examined at each analysis. However, this approach is not readily applied to CF since the CF gene is apparently only expressed at significant levels in tissues that are primarily involved in the pathology of the disease, such as the epithelium lining the lungs and respiratory system, pancreatic ducts, gut, and sweat gland ducts.13 Apart from nasal epithelium, such tissues are not readily available for mRNA analysis. To circumvent this problem we have developed a method to amplify the CF mRNA from peripheral blood lymphocytes. This method relies on cDNA synthesis, followed by two rounds of polymerase chain reaction using nested primers.<sup>4</sup> 'Ectopic' transcription of other genes, including the dystrophin and factor VIII genes, has recently been detected in lymphocytes.5-7

Division of Medical and Molecular Genetics, United Medical and Dental Schools of Guy's and St Thomas's Hospitals, 8th Floor, Guy's Hospital Tower, London SEI 9RT.

G Chalkley, A Harris

Correspondence to Dr Harris, Paediatric Molecular Genetics, Institute of Molecular Medicine, The John Radcliffe Hospital, Headington, Oxford OX3 9DU.

Received for publication 26 March 1991.

Revised version accepted for publication 3 May 1991.

Lymphocytes were isolated from whole blood by Histopaque (Sigma) centrifugation. Cells were washed by phosphate buffered saline and then RNA was extracted by single step guanidinium thiocvanate phenol extraction.8 Alternatively, RNA was isolated from lymphocytes or lymphoblastoid cell lines by guanidinium thiocyanate lysis followed by caesium chloride centrifugation.9 The CF cDNA sequence was divided into eight segments (A to H) as is shown in fig 1. Segments A to F broadly correspond to predicted functional domains of the protein, and segments G and H to the 3' non-coding region of the mRNA. In order to amplify the CF cDNA from lymphocyte RNA, in which the CF gene message is represented at an extremely low level, it was necessary to have two 30 to 35 cycle rounds of polymerase chain reaction (PCR) for each segment, using nested sets of primers. The primer sequences are shown in the table. The first round of PCR was carried out using primer set 1 following cDNA synthesis primed by the 3'20-mer (IL) of each PCR reaction. The second round of PCR amplification was done using primers located inside those used in the first round reaction (primer set 2). Fifty nanograms of the 3' primer for each CF gene segment was annealed to 0.5 to 1 µg of total RNA at 65°C. cDNA was synthesised from this primer with reverse transcriptase (Gibco BRL) in 50 mmol/l Tris-HCl, pH 8.5, 75 mmol/l KCl, 5 mmol/l DTT, 3 mmol/l MgCl<sub>2</sub>, 1.25 mmol/l dNTPs, and 50 units of placental ribonuclease inhibitor (Boehringer, Mannheim) in a total volume of 20 µl at 42°C for 60 minutes. To this was added 30 µl of a premix of PCR buffer containing 67 mmol/l Tris-HCl, pH 8.8, 167 mmol/l (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 6.7 mmol/l MgCl<sub>2</sub>,  $0.17 \text{ mg ml}^{-1}$  BSA,  $0.07\% \beta$ -mercaptoethanol, 500 ng of the 5' primer, 450 ng of the 3' primer, and five units of Taq polymerase (Cetus). The following conditions were used for the PCR reaction: after five minutes denaturation at 94°C, 30 cycles of 60 seconds denaturation at 94°C, 60 seconds annealing at 60°C, five to seven minutes extension at 72°C



Figure 1 Diagram of the CF gene cDNA to show overlapping segments amplified by each set of clustered PCR primers (A-F) and their relation to the predicted functional domains of the protein.

Primer		Sequence		Fragment size
A1R A2R	124 156	CGAGAGACCATGCAGAGGTC GGCCAGCGTTGTCTCCAAAC	- <u></u> 9	1033
A2L A1L		gccgagtgaccgccatgcgc gctccaagagagtcatacca	1189 1232	
B1R B2R	998 1022	GACAAACAGAACTGAAACTG GGAAGGCAGCCTATGTGAGA		898
B2L B1L		agccatcagtttacagacac cagctttctttaaatgttcc	1920 1972	
C1R C2R	1777 1812	GTGGAGGTCAACGAGCAAGA AGCAGTATACAAAGATGCTG		769
C2L C1L		tcttcacttatttccaagcc actcctttaagtcttcttcg	2581 2626	
D1R D2R	2490 2530	GACAACAGCATCCACACGAA GCAAACTTGACTGAACTGGA		729
D2L D1L		gttgtttgagttgctgtgag aattggactcctgccttcag	3259 3283	
E1R E2R	3055 3082	AGATTCTCCAAAGATATAGC GATGACCTTCTGCCTCTTAC		699
E2L E1L		ctgtgagatctttgacagtc gaaatgttgtctaatatggc	3781 3824	
F1R F2R	3722 3754	ACGTGAAGAAAGATGACATC GGCCAAATGACTGTCAAAGA		077
F2L F1L		catgtcaacatttatgctgc cgagctccaattccatgagc	4599 4627	011
GIR	4524	GCTGCTCTGAAAGAGGAGAC		760
G1L		agattataacagccctttcc	5310	
HIR	5127	GAATACCACAGGAACCACAA		945
H1L		gcagtcttcttaagagtcag	6072	777

Primer sequences used for PCR amplification of CF gene cDNA segments.

depending on the length of the cDNA segment; a final polymerisation step was carried out at 72°C for five minutes. A total of 1  $\mu$ l of the first PCR reaction was then transferred to 49  $\mu$ l of a PCR buffer premix as above but containing 500 ng of each primer in the inside pair of the clustered set and 0.5 mmol/l dNTPs. A further 30 to 35 cycles of amplification

were done using the same parameters as for the first reaction.

The products of each PCR reaction are shown in fig 2, where one-fifth of a second round PCR reaction on 1  $\mu$ g of total RNA from lymphoblastoid cell lines (1) and from peripheral blood lymphocytes (2) have been analysed on a 5% polyacrylamide



Figure 2 Fragments A to F of the CF gene, PCR amplified after cDNA synthesis from 1  $\mu$ g of total RNA from (1) a lymphoblastoid cell line and (2) lymphocytes; 10  $\mu$ l of a 50  $\mu$ l PCR reaction separated on a 5% polyacrylamide gel.

minigel. All sets of primers functioned efficiently, though the yield with set C was always lower than with the other primer sets in the same RNA sample. Lowering of the annealing temperature of the PCR reaction to 58°C increased the yield. Each CF cDNA fragment was digested with at least one restriction enzyme to confirm the identity of the PCR product, based on the published cDNA sequence (data not shown).

In order to establish the fidelity of the 'ectopic' CF gene transcript in lymphocytes, we first attempted to detect the  $\triangle$  F508 mutation in exon 10 in known carrier subjects. RNA from the B region of the gene sequence which includes this mutation (fig 1) was reverse transcribed, amplified by PCR, and subjected to chemical mismatch analysis.<sup>10</sup> Where the PCR reaction yielded small amounts of nonspecific product, the fragment of interest was purified on agarose gels before GeneClean (Bio 101) separation. Fig 3 shows a mismatch reaction with different ratios of control to patient ( $\triangle$ F508 carrier) DNA in the hybrid annealing step. Though with ratios of 1:10 and 1:20 control:patient DNA we were unable to detect the three base pair deletion at base 1654, when the ratio was increased to 1:30 or 1:40, mismatch bands of about 635 and 265, corresponding to the two cleavage products caused by the  $\triangle$  F508 deletion, were clearly visible after both osmium and hydroxylamine modification. The three T residues in the mismatch are detected by the osmium tetroxide modification and a C residue adjacent to the deletion, and so destabilised, is modified by hydroxylamine.

A polymorphism has been shown to occur at base 1540 of the CF cDNA sequence<sup>11</sup> where an A or G may occur. A 380 bp mismatch band seen on fig 3 corresponds to a mutation 380 bp from the 3' end of fragment B at 1920 bp. Sequence analysis of cDNA and genomic DNA from this subject showed the A1540 $\rightarrow$ G base change (data not shown). The establishment of a reliable method for detecting the CF gene transcript in peripheral blood lymphocytes and lymphoblastoid cell lines opens up



Figure 3 Autoradiograph of a 6% denaturing polyacrylamide gel showing a chemical mismatch reaction between control normal DNA segment B and the same segment from a CF patient, heterozygous for the  $\Delta$ F508 mutation, after purification of both with Geneclean (Bio 101). Different ratios of probe: patient DNA have been used 1:10 to 1:40. The first four lanes show mismatches after osmium modification and the right four lanes after hydroxylamine modification. Fragment B is 898 bp.

a new approach to the definition of mutations in the CF gene. We have shown that CF gene cDNA isolated by this method reliably reproduces known mutations and polymorphisms in the CF gene including the common  $\triangle$  F508 mutation and the A1540 $\rightarrow$ G polymorphism.

The authors are grateful to the Cystic Fibrosis Research Trust, the Generation Trust, and the Spastics Society for supporting this work. We thank Roli Roberts, Jane Montandon, and Francesco Giannelli for helpful discussions.

- Riordan JR, Rommens JM, Kerem BS, et al. Identification of the cystic fibrosis gene: cloning and characterisation of complementary DNA. Science 1989;245:1066-73.
- 2 Kerem BS, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245:1073-80.
- 3 Harris A, Chalkley GC, Goodman SA, Coleman LS. Expression of the cystic fibrosis gene in early human development. Development 1991;113:305-11.

- 4 Holding C, Monk M. Diagnosis of beta-thalassaemia by DNA amplification in single blastomeres from mouse preimplantation embryos. *Lancet* 1989;ii:523-35.
- Chelly J, Kaplan JC, Maire P, Gautron S, Kahn A. Transcription of the dystrophin gene in human muscle and non-muscle tissues. *Nature* 1988;33:858-60.
  Roberts R, Bentley DR, Barby TFM, Manners E, Bobrow M.
- 6 Roberts R, Bentley DR, Barby TFM, Manners E, Bobrow M. Direct diagnosis of carriers of Duchenne and Becker muscular dystrophy by amplification of lymphocyte RNA. *Lancet* 1990;336:1523-6.
- 7 Berg LP, Wieland K, Millar DS, et al. Detection of a novel point mutation causing haemophilia A by PCR/direct sequencing of ectopically-transcribed factor VIII mRNA. *Hum Genet* 1990;85:655-8.
- 8 Chromczynski P, Śacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
- 9 Chirgwin JM, Przybyla AE, Macdonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. *Biochemistry* 1979;18:5294-9.
   10 Montandon AJ, Green PM, Giannelli F, Bentley DR. Direct
- 10 Montandon AJ, Green PM, Giannelli F, Bentley DR. Direct detection of point mutations by mismatch analysis: application to haemophilia B. Nucleic Acids Res 1989;17:3347-58.
- 11 Kerem BS, Zielenski J, Markiewicz D, et al. Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. Proc Natl Acad Sci USA 1990;87:8446-51.